Pearl Steinzor

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and patient-preferred prep options, study finds.

Knowledge gaps, financial burdens, and skepticism hinder Hispanic men’s participation in the National Diabetes Prevention Program, a study finds.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).

Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute, introduces New Jersey's new state-of-the-art facilities at the Jack & Sheryl Morris Cancer Center.

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.

As clinician shortages grow, hospitals turn to artificial intelligence (AI) and scheduling tools to optimize resources, reduce burnout, and expand patient access—especially in rural communities.

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

Nonalcoholic fatty liver disease (NAFLD) was linked to elevated liver enzymes in type 2 diabetes mellitus (T2DM) in a recent study, urging early detection and comprehensive care.

Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those with higher BSA, a new study finds.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible or deferred newly diagnosed multiple myeloma.

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, discusses the potential consequences of losing free health care screening coverage.

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses the trial design of a study comparing amivantamab with standard chemotherapy to potentially improve treatment outcomes.

Sodium reduction is key to lowering blood pressure in adults with type 2 diabetes, a study finds.

Amivantamab shows promise as a first-line treatment for metastatic colorectal cancer, potentially outperforming standard chemotherapy options.

Artificial intelligence (AI) provides a major tool in the evolution of thoracic care, as clinicians work to catch lung cancer earlier to provide better prognosis.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP), shares updates on the Ensuring Community Access to Pharmacist Services (ECAPS) Act of 2025, which was introduced in the House of Representatives last month.

Leaders in oncology share why the American Society of Clinical Oncology (ASCO) meeting remains a top global gathering for breakthroughs, networking, and lifelong learning.

With potential lung cancer nodules sometimes slipping through the cracks, educating stakeholders about artificial intelligence (AI) that can catch nodules early could be helpful in cancer treatment.

Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center, shares how one mobile health care initiative is addressing critical barriers to medical access for underserved populations.

A groundbreaking trial shows tumor-treating fields enhance survival and quality of life for patients with locally advanced pancreatic cancer.

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared with the general population.

Ponatinib shows promising results in achieving MRD negativity and improved event-free survival in Ph+ ALL patients compared to imatinib, according to ASCO findings.

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide.

Developments in artificial intelligence (AI) can help clinicians to diagnose thoracic conditions that may be miss on first glance.

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.

Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.